O. A. Loginovskaya

O. A. Loginovskaya

Auto-generated profile, based on publicly available information

O. A. Loginovskaya

Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov" of the Ministry of Health of the Russian Federation; Flex Databases LLC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
OLO. A. Loginovskaya
O. A. Loginovskaya
VKV. P. Kolbatov
V. P. Kolbatov
RSR. V. Sukhov
R. V. Sukhov
MRM. S. Ryavkina
M. S. Ryavkina
AKA. S. Kolbin
A. S. Kolbin
Emergent ways to obtain information on the safety of medicinal products give relevance to the implementation of new information technologies into big data analysis in pharmacovigilance.The aim of the study was to systematise data on the use of information technologies for pharmacovigilance process automation and identify problems and limitations that may arise when introducing the technologies.Materials and Methods: the authors analysed literature on the subject matter and the practical experience of Flex Databases with the development of the electronic system for pharmacovigilance data processing designed for marketing authorisation holders.Results: using the electronic pharmacovigilance system by Flex Databases as an example, the authors demonstrated the feasibility of basic, robotic, and cognitive automation and artificial intelligence technologies for data processing. Automation technologies allow the users to streamline information entry, process and analyse data, create reports and metrics, timely submit the reports and metrics to regulatory authorities, and manage risks and safety signals; they also help specialists in decision making. Artificial intelligence technologies (a wide range of technologies including machine learning, neural networks, and automatic natural language processing) are used to collect safety reports, amongst other things, through real-world clinical data analysis; prepare summary reports; and manage risks and safety signals. Moreover, human involvement is necessary only at certain stages, particularly to process the data on exceptional cases and to analyse the results in an expert capacity.Conclusions: there is demand for process automation and artificial intelligence technologies at all stages of collection and analysis of pharmacovigilance information, from receiving a safety report to submitting it to regulatory authorities and identifying a safety signal. The deployment of the technologies within pharmacovigilance systems helps to increase the amount of data processed, among other things as a result of the inclusion of real-world clinical data into the search process. As the technologies reduce the degree of human involvement into routine processes of data collection, entry, verification, and analysis, the likelihood of errors reduces as well, whereas the quality and accuracy of the obtained results improve.

28 August 2023 in Real-World Data & Evidence
Verified
Journal Article
Open access
PDF file
AMA. Sh. Motrinchuk
A. Sh. Motrinchuk
OLO. A. Loginovskaya
O. A. Loginovskaya
VKV. P. Kolbatov
V. P. Kolbatov
Signal detection is a crucial step in the discovery of post-marketing adverse drug reactions. There is a growing interest in using routinely collected data to complement established spontaneous report analyses.The aim. This work aims to systematically review the methods for drug safety signal detection using routinely collected healthcare data and their performance, both in general and for specific types of drugs and outcomes.Metodology. We conducted a systematic review following the PRISMA guidelines, and registered a protocol in PROSPERO.Results. The review included 101 articles, among which there were 39 methodological works, 25 performance assessment papers, and 24 observational studies. Methods included adaptations from those used with spontaneous reports, traditional epidemiological designs, methods specific to signal detection with real-world data. More recently, implementations of machine learning have been studied in the literature. Twenty-five studies evaluated method performances, 16 of them using the area under the curve (AUC) for a range of positive and negative controls as their main measure. Despite the likelihood that performance measurement could vary by drug-event pair, only 10 studies reported performance stratified by drugs and outcomes, in a heterogeneous manner. The replicability of the performance assessment results was limited due to lack of transparency in reporting and the lack of a gold standard reference set.